Benitec Biopharma (BNTC) Assets Average (2020 - 2025)
Benitec Biopharma has reported Assets Average over the past 6 years, most recently at $143.4 million for Q4 2025.
- Quarterly results put Assets Average at $143.4 million for Q4 2025, up 93.93% from a year ago — trailing twelve months through Dec 2025 was $143.4 million (up 93.93% YoY), and the annual figure for FY2025 was $75.9 million, up 167.85%.
- Assets Average reached $143.4 million in Q4 2025 per BNTC's latest filing, up from $97.8 million in the prior quarter.
- Across five years, Assets Average topped out at $143.4 million in Q4 2025 and bottomed at $6.3 million in Q2 2023.
- Median Assets Average over the past 5 years was $17.8 million (2021), compared with a mean of $39.6 million.
- The largest annual shift saw Assets Average crashed 53.93% in 2022 before it soared 429.87% in 2024.
- Over 5 years, Assets Average stood at $15.9 million in 2021, then decreased by 5.75% to $15.0 million in 2022, then skyrocketed by 61.25% to $24.2 million in 2023, then soared by 205.42% to $73.9 million in 2024, then soared by 93.93% to $143.4 million in 2025.
- Business Quant data shows Assets Average for BNTC at $143.4 million in Q4 2025, $97.8 million in Q3 2025, and $102.4 million in Q2 2025.